Researchers have found that Telios Pharmaceuticals Inc.'ssynthetic peptide drug TP-9201, designed to inhibit bloodplatelet aggregation, is capable of preventing blood clottingwithout increasing bleeding time in animal models of heartattack and thrombosis.

Speaking at the 65th Annual American Heart AssociationMeeting in New Orleans this week, Herman Gold ofMassachusetts General Hospital in Boston explained that TP-9201, which specifically blocks the IIb/IIIa receptors onplatelets, does indeed inhibit platelet aggregation in an animalmodel of heart attack treated with thrombolytic therapy.

Moreover, it enhances tissue plasminogen activator's (t-PA)clot-dissolving ability. And Desire Collen and colleagues at theUniversity of Leuven in Belgium showed that TP-9201 is betterat preventing occlusion in a thrombogenic blood vessel thanheparin, aspirin or another specific antagonist of the IIb/IIIareceptor. In both cases, the drug was able to inhibit platelet-mediated clot formation without associated prolonged bleedingtime, an unwanted and often serious side effect.

"Until now, experts have believed it was necessary tocompromise the control of bleeding to prevent thrombosis,"said Michael Pierschbacher, senior vice president and scientificdirector of Telios of San Diego. "These two animal studies showthat this novel inhibitor of platelet aggregation not onlyenhances the effectiveness of thrombolytic therapy, but canalso maintain blood flow without increasing the risk ofbleeding."

Telios had a $15 million partnership with Genentech Inc. ofSouth San Francisco, Calif., to develop TP-9201. But in October,Genentech returned to Telios the worldwide rights to the anti-thrombotic, as well as preclinical data, including animalefficacy, toxicology and formulation.

Telios (NASDAQ:TLIO) intends to file an investigational newdrug (IND) application for the compound in 1993, and is"considering corporate partnerships" for further development,Audrey Keane, director of corporate communications, toldBioWorld.

-- Jennifer Van Brunt Senior Editor

(c) 1997 American Health Consultants. All rights reserved.

No Comments